Home LiteratureArticle Details
PMID: 26267321 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.

Oncotarget ·Vol. 6 ·No. 28 ·2015-09-22 ·Pages 25520-32

Bai H, Li H, Li W, Gui T, Yang J, Cao D, Shen K

Abstract

To explore the genetic and molecular events that control subclones exhibiting distinct invasive/migratory capacities derived from human epithelial ovarian cancer (EOC) cell line A2780 and SKOV3. Single-cell subclones were isolated and established that were derived from the SKOV3 and A2780 cell lines through limiting dilution methodology. Transwell insert assays and MTT assays were performed to screen and identify the subclones exhibiting the highest and the lowest invasive/migratory capacities, and the selected subclones were renamed as A-H (A2780 high), A-L (A2780 low), S-H (SKOV3 high), and S-L (SKOV3 low). Their biological characteristics were evaluated. RNA-Seq was conducted on the targeted subclones. Compared with their corresponding counterparts, A-H/S-H cells exhibited significantly higher invasive/migratory capacities (P < 0.001 and = 0.001, respectively). A-H/S-H cells displayed a clear reduction in doubling time (P = 0.004 and 0.001, respectively), and a significant increase in the percentage of cells in S phase (P = 0.004 and 0.022, respectively). Additionally, the apoptotic rates of A-H/S-H cells were significantly lower than those of A-L/S-L cells (P = 0.002 and 0.026, respectively). At both mRNA and protein levels, caspase-3 and caspase-7 expression were reduced but Bcl-2 expression was increased in A-H/S-H cells. The TrkB (anoikis-related) and Beclin1 (autophagy-related) levels were consistently high and low, respectively, in both A-H/S-H cells. Resistance to chemotherapy in vitro and higher capacities on tumor formation in vivo was presented in both A-H/S-H cells. PI3K/AKT/mTOR pathway components, PIK3CA, PIK3CD, AKT3, ECM1, GPCR, mTOR and PRKCB were increased but that the Nur77 and PTEN were decreased in A-H/S-H cells, identified by RNA-Seq and consistently confirmed by RT-PCR and Western blot analyses. Heterogeneous cell subpopulations exhibiting distinct invasive and migratory capacities co-exist within the SKOV3 and A2780 cell lines. PI3K/AKT/mTOR pathway activation is associated with higher invasive and migratory capacities in subpopulations of human ovarian cancer cell lines. Inhibiting this pathway may be useful for the chemoprevention or treatment of EOC.

Keywords
RNA-Seq cell subclones intratumoral heterogeneity invasion and migration ovarian cancer
MeSH Terms
Animals Antineoplastic Agents/pharmacology Apoptosis Apoptosis Regulatory Proteins/genetics,metabolism Carcinoma, Ovarian Epithelial Cell Line, Tumor Cell Movement/drug effects Cell Proliferation Drug Resistance, Neoplasm Enzyme Activation Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Mice, Inbred BALB C Mice, Nude Neoplasm Invasiveness Neoplasms, Glandular and Epithelial/drug therapy,enzymology,genetics,pathology Ovarian Neoplasms/drug therapy,enzymology,genetics,pathology Phenotype Phosphatidylinositol 3-Kinase/metabolism Proto-Oncogene Proteins c-akt/metabolism Signal Transduction TOR Serine-Threonine Kinases/metabolism Time Factors Xenograft Model Antitumor Assays
Chemicals
Antineoplastic Agents Apoptosis Regulatory Proteins MTOR protein, human Phosphatidylinositol 3-Kinase Proto-Oncogene Proteins c-akt TOR Serine-Threonine Kinases
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Bai Huimin
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing China. | Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, China Capital Medical University, Beijing China.
Li Haixia
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing China.
Li Weihua
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing China.
Gui Ting
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing China.
Yang Jiaxin
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing China.
Cao Dongyan
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing China.
Shen Keng
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing China.
References (56)
56 references, click to expand
  1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
    Int J Cancer. 2015 Mar 1;136(5):E359-86 PMID: 25220842
  2. Defective autophagy control by the p53 rheostat in cancer.
    Cell Cycle. 2010 Jan 15;9(2):250-5 PMID: 20023384
  3. Genomic complexity and AKT dependence in serous ovarian cancer.
    Cancer Discov. 2012 Jan;2(1):56-67 PMID: 22328975
  4. The emerging mechanisms of isoform-specific PI3K signalling.
    Nat Rev Mol Cell Biol. 2010 May;11(5):329-41 PMID: 20379207
  5. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.
    Clin Cancer Res. 2010 Oct 15;16(20):4928-37 PMID: 20876794
  6. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
    J Clin Invest. 2012 Feb;122(2):553-7 PMID: 22214849
  7. Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis.
    Oncogene. 2012 May 3;31(18):2350-61 PMID: 21996737
  8. Protein kinases C isozymes are differentially expressed in human breast carcinomas.
    Life Sci. 2009 May 22;84(21-22):766-71 PMID: 19324060
  9. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3.
    Cell. 2004 Feb 20;116(4):527-40 PMID: 14980220
  10. Downregulation of two isoforms of ubiquitin carboxyl-terminal hydrolase isozyme L1 correlates with high metastatic potentials of human SN12C renal cell carcinoma cell clones.
    Electrophoresis. 2008 Jun;29(12):2651-9 PMID: 18494032
  11. Atg14 and UVRAG: mutually exclusive subunits of mammalian Beclin 1-PI3K complexes.
    Autophagy. 2009 May;5(4):534-6 PMID: 19223761
  12. Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit.
    J Biol Chem. 1998 Mar 20;273(12):7024-9 PMID: 9507010
  13. Ras, PI(3)K and mTOR signalling controls tumour cell growth.
    Nature. 2006 May 25;441(7092):424-30 PMID: 16724053
  14. RNA sequencing identifies novel markers of non-small cell lung cancer.
    Lung Cancer. 2014 Jun;84(3):229-35 PMID: 24751108
  15. Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones.
    J Cancer Res Clin Oncol. 2009 Jul;135(7):909-17 PMID: 19104837
  16. Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer.
    Cancer Sci. 2008 Mar;99(3):543-52 PMID: 18201274
  17. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
    Methods. 2001 Dec;25(4):402-8 PMID: 11846609
  18. New insights into the pathogenesis of serous ovarian cancer and its clinical impact.
    J Clin Oncol. 2008 Nov 10;26(32):5284-93 PMID: 18854563
  19. TopHat: discovering splice junctions with RNA-Seq.
    Bioinformatics. 2009 May 1;25(9):1105-11 PMID: 19289445
  20. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation.
    Nat Biotechnol. 2010 May;28(5):511-5 PMID: 20436464
  21. Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion.
    Biochem Pharmacol. 2013 May 15;85(10):1454-62 PMID: 23500535
  22. Expression and function of TRK-B and BDNF in human neuroblastomas.
    Mol Cell Biol. 1994 Jan;14(1):759-67 PMID: 8264643
  23. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
    N Engl J Med. 2012 Mar 8;366(10):883-92 PMID: 22397650
  24. Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer.
    BMC Cancer. 2012;12:47 PMID: 22284579
  25. Autophagy functions in programmed cell death.
    Autophagy. 2008 Apr;4(3):359-60 PMID: 18212526
  26. Extracellular matrix 1 (ECM1) expression is a novel prognostic marker for poor long-term survival in breast cancer: a Hospital-based Cohort Study in Iowa.
    Ann Surg Oncol. 2009 Aug;16(8):2280-7 PMID: 19521735
  27. The integrin beta1 subunit transmembrane domain regulates phosphatidylinositol 3-kinase-dependent tyrosine phosphorylation of Crk-associated substrate.
    Mol Biol Cell. 2004 Jun;15(6):2558-67 PMID: 15034138
  28. Signaling by distinct classes of phosphoinositide 3-kinases.
    Exp Cell Res. 1999 Nov 25;253(1):239-54 PMID: 10579926
  29. Beclin 1 contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function.
    Cancer Res. 2001 Apr 15;61(8):3443-9 PMID: 11309306
  30. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
    Science. 1997 Mar 28;275(5308):1943-7 PMID: 9072974
  31. Anoikis: cancer and the homeless cell.
    Nature. 2004 Aug 26;430(7003):973-4 PMID: 15329701
  32. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells.
    Cancer Res. 2006 Dec 1;66(23):11399-408 PMID: 17145886
  33. Tetraploidy/aneuploidy and stem cells in cancer promotion: The role of chromosome passenger proteins.
    J Cell Physiol. 2006 Jul;208(1):12-22 PMID: 16331679
  34. Molecular portraits of heterogeneity related to cancer stem cells in human ovarian cancer.
    Int J Gynecol Cancer. 2014 Jan;24(1):29-35 PMID: 24300467
  35. Somatic genetic alterations (LOH) in benign, borderline and invasive ovarian tumours: intratumoral molecular heterogeneity.
    Int J Cancer. 1999 Sep 9;82(6):822-6 PMID: 10446448
  36. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21.
    Genomics. 1999 Jul 1;59(1):59-65 PMID: 10395800
  37. Akt signaling and cancer: surviving but not moving on.
    Cancer Res. 2006 Apr 15;66(8):3963-6 PMID: 16618711
  38. Mutation of the PIK3CA oncogene in human cancers.
    Br J Cancer. 2006 Feb 27;94(4):455-9 PMID: 16449998
  39. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
    Arch Gynecol Obstet. 2014 Dec;290(6):1067-78 PMID: 25086744
  40. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.
    Br J Cancer. 2010 Oct 12;103(8):1139-43 PMID: 20877357
  41. Tumor heterogeneity in the recurrence of epithelial ovarian cancer demonstrated by polycomb group proteins.
    Onco Targets Ther. 2014 Sep 25;7:1705-16 PMID: 25285018
  42. Induction of autophagy and inhibition of tumorigenesis by beclin 1.
    Nature. 1999 Dec 9;402(6762):672-6 PMID: 10604474
  43. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator.
    Oncogene. 2000 Jan 20;19(3):329-36 PMID: 10656679
  44. Olfactomedin III expression contributes to anoikis-resistance in clonal variants of a human lung squamous carcinoma cell line.
    Exp Cell Res. 2012 Mar 10;318(5):593-602 PMID: 22281030
  45. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.
    Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9052-7 PMID: 9256433
  46. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7.
    Biochemistry. 2001 Jan 30;40(4):1117-23 PMID: 11170436
  47. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB.
    Nature. 2004 Aug 26;430(7003):1034-9 PMID: 15329723
  48. The phosphoinositide 3-kinase pathway.
    Science. 2002 May 31;296(5573):1655-7 PMID: 12040186
  49. The biology of ovarian cancer: new opportunities for translation.
    Nat Rev Cancer. 2009 Jun;9(6):415-28 PMID: 19461667
  50. Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.
    Gynecol Oncol. 2008 Sep;110(3):360-4 PMID: 18632143
  51. Metastasis mechanisms.
    Biochim Biophys Acta. 2009 Dec;1796(2):293-308 PMID: 19683560
  52. PI3K pathway alterations in cancer: variations on a theme.
    Oncogene. 2008 Sep 18;27(41):5497-510 PMID: 18794884
  53. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.
    Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3070-4 PMID: 1348364
  54. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours.
    J Pathol. 2007 Feb;211(3):286-95 PMID: 17154249
  55. Metastasis results from preexisting variant cells within a malignant tumor.
    Science. 1977 Aug 26;197(4306):893-5 PMID: 887927
  56. Autophagy and cancer--issues we need to digest.
    J Cell Sci. 2012 May 15;125(Pt 10):2349-58 PMID: 22641689
Article Info
Journal
Oncotarget
Abbr.
Oncotarget
ISSN
1949-2553
Published
2015-09-22
Pages
25520-32
Language
English
Region
United States
NLM ID
101532965
PMCID
PMC4694849
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]